Publications > Journals > Journal of Clinical and Translational Pathology > Article Full Text


Primary Mediastinal Large B-cell Lymphoma: Diagnostic Challenges and Recent Advances

  • Jiehao Zhou1,*  and
  • Huan-You Wang2,* 
 Author information
Journal of Clinical and Translational Pathology 2021;():-

doi: 10.14218/JCTP.2021.00008


Primary mediastinal (thymic) large B-cell lymphoma (PMBL) is a subtype of uncommon aggressive large B-cell lymphomas primarily occurring in mediastinum although rare cases with non-thymic type of PMBL have been reported. Typical PMBL has characteristic clinical, morphological, and immunophenotypic features which the pathologists use as diagnostic paradigm in routine practice. However, the diagnosis can be occasionally challenging due to the overlapping clinicopathologic features with other lymphomas, among which are nodular sclerosis classic Hodgkin lymphoma, systemic diffuse large B-cell lymphoma (DLBCL) involving mediastinum, and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma (gray zone lymphoma). Recent depictions of the characteristic genetic/ molecular aberrations and unique gene expression profiling in PMBL have provided a robust tool to significantly improve the diagnostic accuracy. In addition, the progresses in understanding the pathogenesis of PMBL have paved the way discovering novel therapeutic agents for patients with refractory/relapsed disease.


PMBL, Cytomorphology, Immunophenotype, GEP, Genetic abnormality


Primary mediastinal (thymic) large B-cell lymphoma (PMBL) belongs to the group of aggressive large B-cell lymphomas. It was initially recognized as a rare subtype of diffuse large B-cell lymphoma (DLBCL) in the Revised European American Lymphoma classification in 1994. However, due to its unique clinical, pathologic, immunophenotypic and genomic features, PMBL has been recognized as a separate distinct lymphoma in the World Health Organization (WHO) classification since 2001.1 The aims of this current review are to summarize the clinical, morphologic, and immunophenotypic features of PMBL; illustrate genetic and molecular characteristics of PMBL; and describe the main differential diagnosis of PMBL.

Epidemiology and clinical presentation of PMBL

PMBL constitutes approximately 2–3% of all non-Hodgkin lymphomas and predominantly affects young adults. The median age of patients is 35-years-old with a female:male ratio of ∼2:11,2 although cases from other age groups have been occasionally reported. PMBL typically presents as a bulky (greater than 10 cm in the largest dimension) and fast-growing anterior mediastinal mass, often associated with localized supraclavicular lymph node involvement. Intrathoracic extension into the lungs, chest wall and pericardial and pleural spaces is common, whereas extrathoracic disease, including distant lymphadenopathy and bone marrow involvement, is very rare at initial presentation. Therefore, approximately 80% of patients initially present as stage I or II disease. However, nodal disease and extranodal dissemination to kidney, breast, adrenal cortex, ovary, liver, pancreas, and gastrointestinal organs may uncommonly occur at relapse.3 In addition, rare cases of PMBL present as a non-mediastinal tumor without evidence of mediastinal involvement.4 Due to the bulky disease, approximately 50% of patients have superior vena cava syndrome and present with facial swelling, dyspnea, headache, neck vein distention, and occasionally thrombosis. B symptoms are not uncommon.2

Cytomorphologic and immunophenotypic features of PMBL

Morphologically, the majority of PMBLs show a diffuse infiltrative pattern, although occasional cases with focal vague nodularity have been reported. The most characteristic morphologic feature of PMBL is sclerosis surrounding lymphoma cell nests, producing a so-called alveolar compartmentalization growth pattern (Fig. 1a).1 Sclerosis varies from case to case, ranging from typical delicate compartmentalizing sclerosis, intersecting bands of fibrosis (Fig. 2a), to occasional broad septa of dense collagen. Focal necrosis is sometimes seen. Cytologically, the lymphoma cells are usually medium to large size with irregular nuclear contours, small nucleoli, and abundant clear to eosinophilic cytoplasm (Fig. 1a, b). Not uncommonly, lymphoma cells can display centroblast-like (Fig. 2b), immunoblast-like, or anaplastic morphology (Fig. 2c). Occasionally, neoplastic cells are multinucleated, mimicking Hodgkin-Reed-Sternberg (HRS) cells (Fig. 2d). In addition, the mitotic rate is generally high.5,6

Typical PMBL morphology and immunophenotype.
Fig. 1  Typical PMBL morphology and immunophenotype.

(a) Low-power and (b) high-power magnifications show classical cytomorphologic features of PMBL in a 57-year-old female who had a mediastinal mass. (a) Atypical lymphoid cells are arranged in nests separated by delicate fibrosis, forming an alveolar compartmentalization pattern. (b) Atypical lymphoid cells are medium size with abundant clear cytoplasm (the original magnifications of A and B are 100× and 400×, respectively). The lymphoma cells are strongly and diffusely positive for (c) CD20 (200×) and (d) PAX-5 (200×). However, tumor cells are weakly and focally (∼20%) positive for (e) CD30 (400×). While the lymphoma cells are partially positive for (f) CD23 (400×), both CD23 and CD21 (inset, 40×) show the absence of follicular dendritic cell meshwork despite a nest-like growth pattern.

Representative cases of PMBL with variable morphologic features
Fig. 2  Representative cases of PMBL with variable morphologic features

(H&E, 400×). (a) A case of PMBL from a 16-year-old male shows intersecting fibrosis bands separating lymphoma cells. (b) A case of PMBL from a 26-year-old female presents as sheets of centroblast-like lymphoma cells with delicate fibrosis. (c) A case of PMBL from a 17-year-old female exhibits diffuse proliferation of lymphoma cells with anaplastic morphology. (d) A case of PMBL from a 38-year-old male demonstrates the majority of lymphoma cells with medium size without significant fibrosis. Scattered Hodgkin and Reed-Sternberg (HRS) cells are noted. Additional information regarding case (d): all lymphoma cells, including HRS cells, are positive for CD20; approximately ∼20% of cells are positive for CD30 and CD23 and negative for CD15; no surface light chain expression was detected by flow cytometry. Fluorescence in situ hybridization (FISH) showed three copies of MYC, but no rearrangements of BCL2, BCL6, or MYC were detected. NGS showed amplifications of PD-L1 (CD274), PD-L2 (PDCD1LG2) JAK2 and KDM4C, mutations of IDH1 R132C, ARID1A P94fs*12, B2M L7*, L7fs*34, FBXO11 splice site, 1009-2A>G, and TNFAIP3 F540fs*162, I629fs*71. The overall immunophenotypic and genomic profiles are most compatible with PMBL.

The normal counterparts of PMBL tumor cells are thought to be CD21(−)/CD23(+) medullary thymic B-cells with either a germinal center (GC) or post-GC origin.7 Immunophenotypically, PMBL uniformly expresses leukocyte common antigen CD45 and is positive for pan B-cell membranous markers, including CD19, CD20 (Fig. 1c), and CD79a.1 B-cell transcription factors, such as PAX5 (Fig. 1d), OCT2, PU.1 and BOB1, are expressed with strong nuclear staining.8 CD30 (Fig. 1e) is expressed in ∼70% of cases but is typically a heterogeneously dimmer in comparison to classic Hodgkin lymphoma (cHL) and anaplastic large cell lymphoma.9 In addition, the CD30 expression is often focal, patchy, and only seen in a subset of tumor cells. Although rare EBER positive PMBL cases have been reported,10,11 expression of EBER and/or CD15 in tumor cells opposes the diagnosis of PMBL. The PBML tumor cells are positive for CD23 (Fig. 1f) expression in ∼70% of cases. Despite a common nest-like growth pattern, PMBL lacks follicular dendritic meshwork as demonstrated by negative CD21 staining (Fig. 1f inset). Variable expressions of CD10 (∼20%), BCL6 (50–60%), MUM1 (40–70%), and BCL-2 (30–80%) have also been reported in PMBL.8,12 The expression of human leukocyte antigen (HLA) class I and II molecules are diminished to absent in a majority of PMBL cases in contrast to other B cell lymphomas.1 Surface light chain immunoglobulin expression is non-detectable in ∼50% of cases by flow cytometry analysis.13 The proliferation index determined by Ki-67 immunohistochemistry (IHC) is generally high, ranging from 40% to 90%. While variable MYC protein expression detected by IHC has been found in >90% of PMBLs, only approximately 33% PMBL cases showed high (> 30%) nuclear positivity.14 Of interest, most MYC positive cases have no MYC translocation, and positive MYC expression does not confer a prognostic significance.14 While PMBL is often positive for expression of CD274 (PD-L1) and CD273 (PD-L2, also known as PDCD1LG2), PD-L1 expression can be seen in tumor-associated macrophages, which may complicate the interpretation of PD-L1 expression in lymphoma cells.15,16 Recently, Kim H et al. demonstrated that ∼80% of PMBLs are positive for p63 expression but negative for GATA3 expression.17 Other recent studies have reported that the expressions of PD-L1, PD-L2, MAL, CD200, TNFAIP2, TRAF1, and c-REL have high sensitivity and specificity (both ranging ∼70–90%) in diagnosing PMBL.18,19 As such, the use of some of these new markers, particularly MAL, c-REL, and CD200, is increasing in major academic laboratories.

Gene expression profiling of PMBL

Gene expression profiling (GEP) is a powerful tool to reveal lymphomagenesis. GEP studies20,21 have shown that PMBL has the following features: (1) high expression of genes located at chromosome band 9p24, including JAK2, PD-L1, PD-L2, and SMARCA2 (mainly due to copy number increases); (2) high expression of IL-13 and its downstream effector genes, including JAK2, STAT1, TNF family members, and TRAF1 (TNF receptor associated factor 1); (3) activation of NF-κB pathway manifested by nuclear shuttling of c-REL (2p16); and (4) low expression levels of multiple components of the B-cell receptor cascade, including AKT1, BLK (B-cell lymphocyte kinase), CD10, CD22, FOXP1, and the major histocompatibility complex (MHC) class II components. Interestingly, Rosenwald et al.20 pointed out that PMBL and cHL share fascinating similarities between their GEPs, whereby over 33% of all PMBL signature genes are more highly expressed in cHL, including CD30, MAL, SNFT, TNFRSF6 and TARC. The striking overlapping GEP features between PMBL and cHL also manifest that both PMBL and cHL show amplifications/gains of genes located at 9p2420 and both have low expression of genes involved in the B-cell receptor signaling cascade.22

Recent studies of B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and cHL, commonly referred as gray zone lymphoma (GZL) by Sarkozy et al.23 provided additional information with regard to the GEP of PMBL in relationship between PMBL and thymic subtype of GZL in that thymic type of GZL resembled PMBL but the non-thymic type of GZL resembled DLBCL. These results added to the notion that the specificity of the thymic niche played an important role in the pathogenesis of PMBL, nodular sclerosis classic Hodgkin lymphoma (NSCHL), and thymic subtype of bona fide GZL.

Genetic/chromosomal aberrations

The detection rate of MYC alterations varies depending on the method used. For example, Scarpa et al.24 reported that 25% of PMBL exhibited MYC alternations using Southern blotting and PCR-single strand conformation polymorphism (SSCP); however, only 6.25% (2/32) had rearrangement of the 2nd/3rd exon, which is characteristic of the translocations found in sporadic Burkitt lymphoma. BCL2 and BCL6 translocations were absent in the 16 PMBLs studied.25 Chromosomal translocation of MHC class II transactivator (CIITA) on chromosome 16p13 has been reported in 38% of PMBL.26 It has been shown that fusion of CIITA, which is the master transcriptional regulator of MHC class II expression, resulted in decreased surface HLA-DR expression. This decreased expression was correlated to the loss of HLA-DR expression, a phenomenon rarely seen in mature and immature B-cell lymphoma/leukemia, that was identified in ∼20% of PMBL.26 Of pertinent note, identical CIITA fusion was also found in 15% of cHL,26 providing additional evidence that mediastinal PMBL and cHL share overlapping genetic features. Rearrangement of chromosome 9p24.1 containing programmed death ligand (PDL) was found in 20% of 125 PMBL cases studied.27 Moreover, 9p24.1 locus contains several important genes, including CD274 (PD-L1) and CD273 (PDCD1LG2, PD-L2).

Genomic landscape of PMBL

The genomic landscape used in this study refers to genomic changes other than chromosomal translocations, as aforementioned above, and includes gains/amplification due to copy number alterations (CNA), insertions, deletions, and mutations.

Immunoglobulin (Ig) genes

Despite that 50% PMBL cases did not express surface kappa or lambda light chains,13 PMBL showed monoclonal Ig rearrangement. In addition, there is evidence of somatic hypermutation (SHM) and heavy chain class switch but without ongoing mutational activity.28


Gains/amplifications of certain chromosomal regions, such as chromosome 9p24, are a frequent feature of PMBL. For instance, a gain of chromosome 9p24.1 with a 5.6-fold higher expression of CD273 (PD-L2) was found to be the overall best PMBL distinction compared to DLBCL.20 In fact, copy number changes of PD-L1 (CD274) and PD-L2 (CD273) were reported in 71% of cases.21 Other amplified genes from 9p24 locus included JAK2 and SMARCA2.20 The expression of PD-L2 was easily assessed by IHC and was associated with gains of copy numbers.16 Amplification of 2p16.1 locus, where the c-REL gene resides, was observed in 41% of PMBLs.29 Comparative genomic hybridization (CGH) also revealed significant gains of chromosomes 9, 19, and X and a loss of 4 in PMBL compared to DLBCL.30

Genes mutations

Large-scale and high-throughput tools, such as next generation sequencing (NGS), have revolutionized our understanding of the mutational landscape of PMBL, which is described in following subsections.

JAK-STAT and NF-kB pathways

Recurrent somatic genomic abnormalities in JAK-STAT and NF-κB signaling pathways were traditionally regarded as the genetic hallmark of PMBL. JAK/STAT pathway transfers signals from cell-membrane receptors to the nucleus and is essential for a wide range of cytokines and growth factors leading to critical cellular events, such as hematopoiesis and immune system development. The most common molecular abnormalities identified in PMBL include JAK2 copy number gain on chromosome 9p24 band SOCS1 structure variant and somatic mutations in IL4R, STAT6, SOCS1, CSF2RB, PTPN1, and CISH. The end effect of these gene alterations is the constitutive activation of the JAK/STAT pathway, which in turn provides lymphoma cells with a proliferative advantage.31 NF-κB signaling pathway activation is another important dysregulated pathway in the pathogenesis of PMBL. The most common genetic abnormalities in this pathway include chromosomal gains and amplifications of the REL gene locus on chromosome 2p16, BCL10 (1p22), and MALT1 (18p21); chromosome deletion and biallelic inactivating mutations of TNFAIP3 on chromosome 6q23; and inactivating mutation of NFKBIE. Both TNFAIP3 and NFKBIE are negative regulators of the NF-κB pathway. In contrast, mutations of NFKBIA, a member of NF-κB pathway and often mutated in CHL, were absent in PMBL and cause constitutive NF-κB pathway activation.32

Tumor microenvironment

The tumor microenvironment changes involving immune evasion in PMBL lymphomagenesis have been increasingly studied particularly with the advent of therapy using immune checkpoint inhibitors. Copy number changes of PD-L1 (CD274) and PD-L2 (CD273) were already discussed above.19 Genetic alterations discovered in other genes in this pathway include B2M2-microglobulin), IL13RA, and CD58,31 which in turn lead to decreased expression of MHC I and II molecules.

Interferon response elements pathway

Mottok et al.33 recently performed whole-exome sequencing of a large cohort of PMBL cases and identified the interferon response factor (IRF) pathway as a potential oncogenic pathway in approximately 50% of PMBL cases. Recurrent oncogenic mutations have been seen in multiple IRF pathway members, including IRF2BP2, IRF4, IRF8, and IRF1, in a mutually exclusive pattern. IRF4 and IRF8 transcription factors are known to play an important role in B-cell development as well as in the germinal center response. The mutations of these genes dysregulate B-cells, facilitating tumorigenesis. In addition, this whole-exome sequencing study provides additional evidence that PMBL is distinct from DLBCL in terms of gene expression level, mutational landscape, and oncogenic driver genes. Conversely, PMBLs have significant overlapping driver gene mutations with classic Hodgkin lymphoma, further establishing the relation between PMBL and cHL.

Interleukin (IL-4)/IL-13 signaling pathway

Significantly increased expression of IL-4 induced gene 1 was observed in 94% (16/17) of PMBLs in contrast to low expression in 67% of DLBCL (12/18).34 PMBL also expressed high levels of IL-13, IL-13 receptor α1 and its downstream effector genes.22 Although STAT6 is a downstream effector gene of IL-13 and phosphorylated STAT6 (P-STAT6) is highly expressed in PMBL [72.7% (8/11) in comparison to 10% (1/10) in DLBCL, it was shown that upregulation of P-STAT6 was not via IL-13, but by high expression of JAK2.35

GEP and genomic analysis of PMBL have led to improved accuracy of PMBL diagnosis. For instance, Mottok A. from the Mayo Clinic recently developed a molecular assay to distinguish PMBL from DLBCL using routinely available formalin-fixed paraffin-embedded tissue biopsies.36 The so-called Lymph3Cx assay is a quantitative gene RNA expression assay that analyzes 58 genes using the Nanostring platform. Of these 58 genes, 24 genes are overexpressed in PMBL and 6 genes are overexpressed in DLBCL. The rest of genes allow cell-of-origin (COO) determination in DLBCL. The assay not only distinguishes PMBL from DLBCL NOS, but also provides COO assignments to DLBCL NOS. Under the appropriate clinical circumstances, PMBL becomes a molecular diagnosis. Furthermore, the identification of recurrent genetic abnormalities in PMBL has provided novel targets in precision treatment. Agents, such as small molecule inhibitors of the JAK/STAT pathway and immune checkpoint inhibitors, have great potential in disease management.

Differential diagnosis of PMBL

The main differential diagnoses of PMBL are lymphomas involving mediastinum, namely NSCHL, GZL, and DLBCL, NOS. Despite similar and overlapping GEPs and genomic landscapes between NSCHL and PMBL as mentioned above, NSCHL should be readily distinguished from PMBL. While PMBL contains HRS-like cells, the cellular components from these two entities are quite different. Specifically, PMBL contains mononucleated medium to large size lymphoma cells, while NSCHL consists of background inflammatory cells. CD30 and PAX5 are uniformly and weakly positive in NSCHL, but only variably positive and strongly positive in PMBL, respectively. Other B-cell specific transcription factors like BOB1 and Oct2 are strongly positive in PMBL, but only positive in a small fraction of NSCHL. PMBL has a strong expression of common B-cell antigens except dim CD22, whereas NSCHL does not express these antigens except variable and weak CD20. A recent report demonstrated that the majority of NSCHL is positive for GATA3 expression with no p63 expression, while PMBL is positive for p63 expression but negative for GATA3 expression.17

The differential diagnosis between PMBL and GZL is challenging, partially because GZL is an evolving entity, and the diagnostic criteria continue to emerge. Based on mutational analysis, GZL is divided into thymic GZL (involving the thymic niche, the traditional GZL) and non-thymic GZL.37 Thymic GZL involves the mediastinum of young males and is associated with a more aggressive clinical course than NSCHL or PMBL. Non-thymic GZL is rarely reported and occurs more frequently in older patients. By definition, GZL demonstrates morphologic and immunophenotypic overlapping features with both PMBL and cHL but does not fulfill the diagnostic criteria of either entity.1 GZL also commonly exhibits confluent sheets of tumor cells, with a background containing a paucity of inflammatory cells. Variable fibrosis can be present, including extensive coarse and fine compartmentalizing fibrosis. Cytomorphologically, neoplastic cells exhibit a broad range of size and shape from centroblast-like and immunoblast-like to Hodgkin-like cells in different areas of the same case. The immunophenotype of GZL is also variable with transitional and divergent patterns of both PMBL and cHL. Tumors morphologically resembling cHL usually show strong CD20, strong PAX-5, weak/absent CD30, and absent CD15 expression. Comparatively, tumors morphologically mimicking PMBL are frequently positive for CD30 and CD15 but negative for CD20 and CD79a. All GZLs should show expression of at least one B-cell marker, such as CD20, CD79a, and PAX-5. MUM1 and CD45 are invariably positive, and MAL expression is identified a significant subset of GZL.1,38,39

Distinguishing PMBL from systemic DLBCL, NOS involving mediastinum can be challenging in certain clinical settings. Systemic DLBCL, NOS can occasionally present as a mediastinal mass with or without extra-mediastinal involvement. The diagnosis of PMBL is relatively straightforward if the lymphoma exhibits the typical morphology and immunophenotypic features of PMBL, including medium to large-sized cells with occasional multilobated nuclei, abundant clear cytoplasm in the background of fibrosis, variable CD30, and CD23 expression.1 However, if the typical morphology and immunophenotypic features are absent, the definitive diagnosis of PMBL versus systemic DLBCL with mediastinal involvement is extremely difficult to render. On the other hand, there are occasional reports describing large B-cell lymphoma with typical pathologic features of PMBL but without detectable mediastinal involvement. The differential diagnosis in such instances includes extra-mediastinal PMBL vs systemic DLBCL with PMBL features. Since the management and prognostics of PMBL and systemic DLBCL are different, a definitive diagnosis is clinically desirable. The most recent advent of the Lymph3Cx assay based on molecular profiling of tumors has proved to accurately distinguish PMBL from DLBCL, making PMBL a molecular diagnosis.36 Moreover, appropriate applications of this assay could improve the diagnostic accuracy for patients with PMBL. The differential diagnoses of PMBL are summarized in Table 1.

Table 1

Comparison of PMBL, GZL, NSCHL, and DLBCL, NOS

PMBLGZLNSCHLDLBCL, NOS, with mediastinal involvement
Age (median)3520–4015–3570
Location (mediastinum)Anterior mediastinumMediastinumMediastinum (80% of cases)Rare
Location (other than mediastinum)Lung, pleura, pericardium, breastOther locationsOther locationsGI, BM, liver, muscle
Growth patternD or NDND
Presence of fibrosisYesVariableYesNo
Presence of HRS cellsYesYesYesNo
Expression of common B-cell antigens CD19, CD20, CD79aYesVariableNo (but dim CD20 can be seen ∼20%)Yes
Expression of B-cell transcription factors (BOB1 and OCT2)YesYesAbsent or partially and weaklyYes
Expression of CD2371–95%67%9%12%
Expression of CD45YesYesNoYes
Expression of PAX-5 and its intensityYesYesYes, but dimYes
Expression of surface kappa or lambda by FCM∼50%VariableNoVast majority
Rearrangement of IgYesYesYes (among enriched HRS cells)Yes
Somatic hypermutation of IgHigh loadNot knownNot knownPresence in ABC type
Ongoing somatic hypermutation of IgAbsenceNot knownNot knownPresence in GC subtype
Gene expression profilingPlease see TextThymic GZL similar to PMBL and NSCHLSimilar to PMBLDiverse
Translocation of MYCAbsent or rareAbsentAbsent5–8%
Translocation of BCL2Absent or rareAbsentAbsent5–40%
Translocation of BCL6Absent or rareAbsentAbsent15–30%

Treatment of PMBL

Historically, PMBL was treated as a variant of DLBCL using the combination of rituximab with CHOP/CHOP-like regimens followed by mediastinal radiation therapy. Although this regimen has resulted in favorable outcomes for most patients, exposure to radiation may pose an adverse effect in young patients. Currently, many medical centers in the United States have considered using more intensive regimens, such as EPOCH-R or DA-EPOCH-R without mediastinal radiation, as the standard treatment for PMBL.40 For refractory or relapsing disease, high-dose therapy followed by auto-SCT is regarded as the standard of care. More recently, immune checkpoint inhibitor pembrolizumab has demonstrated highly effective and safe antitumor activities in clinical trials41 and has received FDA approval for treating patients with chemotherapy-refractory PMBL. JAK/STAT pathway inhibitors and CD19 CAR-T therapy are among other novel agents with great potential in PMBL management.


In summary, PMBL is an uncommon subtype of large B-cell lymphoma that primarily involves the mediastinum. PMBL displays a relatively unique GEP and mutational landscape that resembles NSCHL compared to DLBCL and has a better 5-year survival than DLBCL. While classical PMBL with typical diagnostic morphologic and immunophenotypic features poses minimal diagnostic challenges, atypical PMBL should be distinguished from cHL, GZL, and systemic DLBCL, NOS involving the mediastinum. It is expected that the appropriate application of available molecular tools will help to significantly increase the diagnostic accuracy of PMBL in the future.



B-cell lymphocyte kinase


comparative genomic hybridization


classic Hodgkin lymphoma


class II transactivator




diffuse large B-cell lymphoma


gene expression profiling


gray zone lymphoma


Hodgkin and Reed-Sternberg






interferon response factor


major histocompatibility class


nodular sclerosis classic Hodgkin lymphoma


primary mediastinal large B-cell lymphoma


somatic hypermutation


TNF receptor associated factor 1


world health organization




Ethical statement

Written informed consents were obtained from all patients for publication of the images described in the figures.



Conflict of interest

Dr. Zhou has been an editorial board member, and Dr. Wang has been an editor-in-chief of Journal of Clinical and Translational Pathology since May 2021. The authors have no other conflicts of interest to declare.

Authors’ contributions

Dr. Zhou and Dr. Wang contributed equally to initiating the study, writing the manuscript, and critical revision. They have approved the final manuscript.


  1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.In:Swerdlow SH,Swerdlow SH,Campo E,Harris NL,Jaffe ES,Pileri SA,Stein H,et al editors. WHO Classification of Tumours, Revised 4th ed.Lyon, France: International Agency for Reasearch on Cancer (IARC).2017.pp.314-316 :314-316
  2. Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2008;2008(1):349-358 View Article
  3. Barth TF, Leithauser F, Joos S, Bentz M, Möller P. Mediastinal (thymic) large B-cell lymphoma: where do we stand?. Lancet Oncol 2002;3(4):229-234 View Article
  4. Yuan J, Wright G, Rosenwald A, Steidl C, Gascoyne RD, Connors JM, et al. Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. Am J Surg Pathol 2015;39(10):1322-1330 View Article
  5. Paulli M, Strater J, Gianelli U, Rousset MT, Gambacorta M, Orlandi E, et al. Mediastinal B-cell lymphoma: a study of its histomorphologic spectrum based on 109 cases. Hum Pathol 1999;30(2):178-187 View Article
  6. Pileri SA, Zinzani PL, Gaidano G, Falini B, Gaulard P, Zucca E, et al. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma 2003;44(Suppl 3):S21-S26 View Article
  7. Dunleavy K, Steidl C. Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma. Semin Hematol 2015;52(2):119-125 View Article
  8. Pileri SA, Gaidano G, Zinzani PL, Falini B, Gaulard P, Zucca E, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003;162(1):243-253 View Article
  9. Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol 1999;112(2):241-247 View Article
  10. Kim SJ, Hyeon J, Cho I, Ko YH, Kim WS. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas. Cancer Res Treat 2019;51(2):611-622 View Article
  11. Maracaja DLV, Puthenpura V, Pels SG, O’Malley DP, Sklar JL, Finberg KE, et al. EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. Appl Immunohistochem Mol Morphol 2020;28(10):725-730 View Article
  12. De Mello CA, De Andrade VP, De Lima VC, Carvalho AL, Soares FA. Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma. Leuk Lymphoma 2011;52(8):1495-1503 View Article
  13. Weinberg OK, Rodig SJ, Pozdnyakova O, Ren L, Arber DA, Ohgami RS. Surface Light Chain Expression in Primary Mediastinal Large B-Cell Lymphomas by Multiparameter Flow Cytometry. Am J Clin Pathol 2015;144(4):635-641 View Article
  14. Li KD, Miles R, Tripp SR, Glenn MJ, Perkins SL, Salama M. Clinicopathologic evaluation of MYC expression in primary mediastinal (thymic) large B-cell lymphoma. Am J Clin Pathol 2015;143(4):598-604 View Article
  15. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013;19(13):3462-3473 View Article
  16. Shi M, Roemer MG, Chapuy B, Liao X, Sun H, Pinkus GS, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 2014;38(12):1715-1723 View Article
  17. Kim HJ, Kim HK, Park G, Min SK, Cha HJ, Lee H, et al. Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma. Diagn Pathol 2019;14(1):133 View Article
  18. Copie-Bergman C, Plonquet A, Alonso MA, Boulland ML, Marquet J, Divine M, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 2002;15(11):1172-1180 View Article
  19. Dorfman DM, Shahsafaei A, Alonso MA. Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers. Mod Pathol 2012;25(12):1637-1643 View Article
  20. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198(6):851-862 View Article
  21. Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood 2019;134(10):802-813 View Article
  22. Savage KJ, Monti S, Kulok JL, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102(12):3871-3879 View Article
  23. Sarkozy C, Chong L, Takata K, Chavez EA, Miyata-Takata T, Duns G, et al. Gene expression profiling of gray zone lymphoma. Blood Adv 2020;4(11):2523-2535 View Article
  24. Scarpa A, Moore PS, Rigaud G, Inghirami G, Montresor M, Menegazzi M, et al. Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc. Br J Haematol 1999;107(1):106-113 View Article
  25. Tsang P, Cesarman E, Chadburn A, Liu YF, Knowles DM. Molecular characterization of primary mediastinal B cell lymphoma. Am J Pathol 1996;148(6):2017-2025
  26. Steidl C, Shah S, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011;471(7338):377-381 View Article
  27. Twa DDW, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014;123(13):2062-2065 View Article
  28. Leithäuser F, Bäuerle M, Huynh MQ, Möller P. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood 2001;98(9):2762-2770 View Article
  29. Weniger MA, Gesk S, Ehrlich S, Martin-Subero JI, Dyer MJ, Siebert R, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer 2007;46(4):406-415 View Article
  30. Palanisamy N, Abou-Elella AA, Chaganti SR, Houldsworth J, Offit K, Louie DC, et al. Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Genes Chromosomes Cancer 2002;33(2):114-122 View Article
  31. Lees C, Keane C, Gandhi MK, Gunawardana J. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol 2019;185(1):25-41 View Article
  32. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011;118(10):2659-2669 View Article
  33. Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood 2019;134(10):802-813 View Article
  34. Copie-Bergman C, Boulland ML, Dehoulle C, Möller P, Farcet JP, Dyer MJ, et al. Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood 2003;101(7):2756-2761 View Article
  35. Guiter C, Dusabter-Fourt I, Copie-Bergman C, Boulland ML, Le Gouvello S, Gaulard P, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004;104(2):543-549 View Article
  36. Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood 2018;132(22):2401-2405 View Article
  37. Sarkozy C, Hung SS, Chavez EA, Duns G, Takata K, Chong LC, et al. Mutational landscape of gray zone lymphoma. Blood 2021;137(13):1765-1776 View Article
  38. Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, et al. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv 2017;1(26):2600-2609 View Article
  39. Egan C, Pittaluga S. Into the gray-zone: update on the diagnosis and classification of a rare lymphoma. Expert Rev Hematol 2020;13(1):1-3 View Article
  40. Giulino-Roth L. How I treat primary mediastinal B-cell lymphoma. Blood 2018;132(8):782-790 View Article
  41. Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol 2019;37(34):3291-3299 View Article
  • Journal of Clinical and Translational Pathology
  • eISSN 2771-165X

Primary Mediastinal Large B-cell Lymphoma: Diagnostic Challenges and Recent Advances

Jiehao Zhou, Huan-You Wang
  • Reset Zoom
  • Download TIFF